Medtronic to acquire AI-enabled FFR specialists CathWorks for up to $585M

February 4, 2026 - 01:01

In a strategic move to bolster its cardiovascular offerings, medical technology giant Medtronic has announced an agreement to acquire CathWorks, a pioneer in artificial intelligence-driven fractional flow reserve (FFR) imaging. The deal, valued at up to $585 million, signals a significant investment in the digital future of cardiac catheterization labs.

The acquisition builds upon an existing relationship, as Medtronic has held a minority stake in CathWorks for several years and entered a co-promotion agreement with the company in 2022. CathWorks' flagship technology, the FFRangio System, utilizes AI to create a 3D map of coronary blood flow from a standard angiogram. This provides physicians with critical, real-time physiological data to assess the severity of blockages without the need for additional invasive wires or drugs.

Upon finalization, the transaction is poised to substantially increase Medtronic's footprint and innovation capacity within the hospital cath lab. Integrating CathWorks' AI-powered diagnostic software with Medtronic's extensive portfolio of coronary devices and therapies aims to streamline workflows and enhance decision-making for clinicians treating coronary artery disease. The move underscores a growing industry trend where traditional medical device companies are actively integrating advanced digital and AI tools to create more comprehensive solutions for improved patient care.